An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
An Extension Study to Assess the Long-term Safety and Efficacy of Pasireotide in Patients With Acromegaly
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth
 hormone (GH), generally caused by a GH-secreting pituitary adenoma. This study will assess
 the long-term safety and efficacy of pasireotide in patients with acromegaly.
Inclusion Criteria:

 -  Patients who have completed all four treatment regimens in the core study CSOM230B2201
 and achieved biochemical control in GH and IGF-1 levels after at least one month of
 pasireotide administration at any of the three doses

 -  Patients who did not experience any unacceptable adverse events or tolerability issues
 during the core study CSOM230B2201

 Exclusion Criteria:

 -  Patients who experienced or developed compression of the optic chiasm causing any
 visual field defect during the core study CSOM230B2201

 -  Patients who required a surgical intervention for relief of any sign or symptom
 associated with tumor compression during the core study CSOM230B2201 Patients who
 experienced or developed congestive heart failure, unstable angina, sustained
 ventricular tachycardia, ventricular fibrillation or acute myocardial infraction
 during the core study CSOM230B2201

 Other protocol-defined inclusion/exclusion criteria may apply.